20
Participants
Start Date
September 30, 2011
Primary Completion Date
February 28, 2015
Study Completion Date
February 28, 2015
ranibizumab 0.5 or 2.0 mg/0.05 cc
ranibizumab (3:1 ratio of 2mg:0.5 mg ranibizumab) administered in three initial monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and 12 month off drug safety follow up.
Southeast Retina Center, Augusta
Collaborators (1)
Genentech, Inc.
INDUSTRY
Southeast Retina Center, Georgia
OTHER